What’s next for CRISPR & gene therapy, plus a China Summit Preview
Emerging Company Spotlight: Elpiscience and Rectify
On the BioCentury This Week podcast, BioCentury’s editors dig into the latest trends in CRISPR and gene therapy, both in the lab and at biopharmas.
Senior Editors Karen Tkach Tuzman and Lauren Martz discuss advances in gene editing machinery that have come via engineering or through the discovery of new natural nucleases with advantageous properties, and takeaways from BioCentury’s analysis of what 51 gene therapy companies founded in the last five years are working on. Martz also previews BioCentury’s look at gene therapy deals in the past two years.